Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study

Table 5 Treatment discontinuations

Reason for discontinuation, n (%)	Hepatic function
Reason for discontinuation, n (%)	Normal (n = 11)	Mild impairment (n = 17)	Moderate impairment (n = 14)	Severe impairment (n = 4)	Total (N = 46)
AEs	1^a	1	4^a	0	6
Disease progression	7	13	7	2	29
Investigator decision	0	1	0	0	3
Patient request/consent withdrawn	0	0	2	0	2
Death	1	2	1	2	6

AE adverse event
^aConsidered treatment related (pneumonitis in one normal hepatic function patient and one each pneumonitis, infusion reaction, and increased blood bilirubin in the moderate hepatic impairment group)

ISSN: 2162-3619